Home
Learn More
Features & Pricing
Success Stories
Contact Us
Search Archives
PRWeb Direct
Submit Release
July 23, 2008
 
Industry Categories  
News by Country  
News by MSA  
Todays News  
Browse by Day  
PR Trackbacks™  
Featured Videos  
ViewNews™  
eBook Digests  
RSS  
PRWeb, a leader in online news and press release distribution, has been used by more than 40,000 organizations of all sizes to increase the visibility of their news, improve their search engine rankings and drive traffic to their Web site.
 
Close Move
All Press Releases for February 9, 2007 Subscribe to this News Feed      
 

Anna Nicole Smith Possibly Died of Flu 'Cytokine Storm'

GenoMed® (Pink Sheets:GMED), a Next Generation Disease Management company, announced today that Anna Nicole Smith possibly died of a "cytokine storm" associated with the flu. GenoMed has obtained excellent results against the "cytokine storm" for the past five years, using already-existing blood pressure pills present in most drugstores on earth. Ms. Smith's death may have been preventable.

We've found a novel approach to viral disease for the general population. If the CDC and WHO hadn't ignored us for the past 5 years, Anna Nicole Smith might have heard about us, used our approach to reduce her flu symptoms, and still be alive. Every drugstore on earth carries the drugs we use. And they're a lot safer than aspirin.
Ms. Smith's attorney, Ron Rale, told The Associated Press that he had talked to her on Tuesday or Wednesday, and she had flu symptoms and a fever.

GenoMed recognized before anyone else that what kills healthy people from a viral disease is the "cytokine storm" their own body creates to fight the virus. For five years, GenoMed has been running free clinical trials for West Nile virus encephalitis, regular influenza, and avian influenza ("bird flu"). Its treatments are the subject of pending patents.

Unfortunately, the public health authorities have been completely uncooperative. For example, the CDC tried to shut down GenoMed's WNV trial in June 2004. And the WHO has yet to respond to GenoMed about the bird flu. Instead, the WHO has urged governments to stockpile Tamiflu at the cost of billions of dollars, even though Tamiflu is known to have a 10% viral resistance rate. Since GenoMed targets the host's response, rather than trying to kill the virus, there should be no viral resistance.

Said Dr. David Moskowitz, GenoMed's CEO and Chief Medical Officer, "We've found a novel approach to viral disease for the general population. If the CDC and WHO hadn't ignored us for the past 5 years, Anna Nicole Smith might have heard about us, used our approach to reduce her flu symptoms, and still be alive. Every drugstore on earth carries the drugs we use. And they're a lot safer than aspirin."

About GenoMed

Patients are encouraged to download GenoMed's approach to avian influenza from its website, www.genomed.com. GenoMed estimates that it can already save 10% of healthcare costs and extend life by 5 years. Patients are encouraged to contact Dr. Moskowitz (dwmoskowitz@genomed.com) about joining GenoMed's Clinical Outcomes Improvement Program (COIP®).

Safe Harbor Statement

This press release contains forward-looking statements, including those statements pertaining to GenoMed, Inc.'s (the Company's) finances and treatments. The words or phrases "ought to," "should," "could," "may," or similar expressions are intended to identify "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from those projected in the forward-looking statements as a result of a number of risks and uncertainties, including but not limited to our research and development being subject to scientific, economic, regulatory, governmental, and technological factors. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. Unless otherwise required by applicable law, we specifically disclaim any obligation to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.

Post Comment:
Trackback URL: http://www.prweb.com/pingpr.php/Q291cC1IYWxmLVNpbmctSG9yci1NYWduLVplcm8=

Technorati Tags

Bookmark -  Del.icio.us | Digg | Furl It | Spurl | RawSugar | Simpy | Shadows | Blink It | My Web


OPTIONS
Printer Friendly Version
Download PDF Version
Download Reader Version
BlogThis
ShareIt

Share The News

Submit this press release easily to any of these major bookmarking and social media sites.

CONTACT INFORMATION

GenoMed, St. Louis
CEO
David W. Moskowitz, MD, 314-983-9933
dwmoskowitz@genomed.com

ATTACHED FILES

There are no multimedia files attached to this release. If this is your release, you may add images or other multimedia files by creating a Smart News Release at Business Wire.

ABOUT PRESS RELEASES
If you have any questions regarding information in these press releases please contact the company listed in the press release. Please do not contact PRWeb. We will be unable to assist you with your inquiry. PRWeb disclaims any content contained in these releases. Our complete disclaimer appears here.
 
Disclaimer: If you have any questions regarding information in these press releases please contact the company listed in the press release.
Please do not contact PRWeb®. We will be unable to assist you with your inquiry.
PRWeb® disclaims any content contained in these releases. Our complete disclaimer appears here.

© Copyright 1997-2008, Vocus PRW Holdings, LLC.
Vocus, PRWeb and Publicity Wire are trademarks or registered trademarks of Vocus, Inc. or Vocus PRW Holdings, LLC.

Terms of Service | Privacy Policy | Copyright